Therapeutic Drug Monitoring of Infliximab in Jordanian Patients

Background: Infliximab is a critical biologic therapy for severe inflammatory diseases, but its efficacy can be compromised by the development of anti-drug antibodies (ADAs). Therapeutic drug monitoring (TDM) is a recommended strategy to optimize treatment, but its implementation in Jordan has been limited. This study is the first to evaluate infliximab TDM in a Jordanian patient cohort.Methods: Seventy-three Jordanian patients with inflammatory bowel disease (IBD) were recruited for this study. Trough levels of infliximab and ADAs were measured using enzyme-linked immunosorbent assay (ELISA). Clinical and demographic data, including Erythrocyte Sedimentation Rate (ESR) and smoking status, were collected and analyzed.Results: A significant negative correlation was observed between infliximab trough levels and ADA levels (r = -0.69, p < 0.001). A notable 33.8% of patients developed high ADA titers (>100 ng/mL). ESR and smoking were significantly associated with lower infliximab levels and higher ADA levels. Other factors, such as hormones (Free T4, TSH), vitamins, and kidney and liver function tests, did not show significant correlations.Conclusion: This study provides the first evidence from Jordan supporting the utility of TDM for infliximab. The high prevalence of ADAs and their correlation with negative clinical outcomes underscore the need for routine TDM to guide dosing strategies and improve patient outcomes in Jordan. The findings also highlight ESR and smoking as potential risk factors for treatment failure.

Authors

Institutions

Publication Details

Journal
Journal of Research in Pharmacy
Published
2026-11-12
DOI
https://doi.org/10.12991/jrespharm.1908394
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Therapeutic Drug Monitoring of Infliximab in Jordanian Patients

Nasir Idkaidek, Luay Abu-Qatouseh, Abdo Mahli, Asma Zinati et al.
Journal of Research in Pharmacy
Inflammatory Bowel Disease
article

Therapeutic Drug Monitoring of Infliximab in Jordanian Patients

Nasir Idkaidek, Luay Abu-Qatouseh, Abdo Mahli, Asma Zinati, Laith Alshoaibi, Hana'a Khalaf, Salim Hamadi, Haya Tuffaha, Ahmad Ayesh, Rola Alqashash, Mohammad Quta, Mahmoud Abualhaj, Mohammad Ibrahim, Moyad Qudah, Alaa Al-Hanahen, Zaid Alshawahin, Aseel Aljhani, Maisa Matahen, Marwan Al-Armouti, Motaz Jibril, Aya Tarawneh, Karmen Abusaif
article en

Abstract

Background: Infliximab is a critical biologic therapy for severe inflammatory diseases, but its efficacy can be compromised by the development of anti-drug antibodies (ADAs). Therapeutic drug monitoring (TDM) is a recommended strategy to optimize treatment, but its implementation in Jordan has been limited. This study is the first to evaluate infliximab TDM in a Jordanian patient cohort.Methods: Seventy-three Jordanian patients with inflammatory bowel disease (IBD) were recruited for this study. Trough levels of infliximab and ADAs were measured using enzyme-linked immunosorbent assay (ELISA). Clinical and demographic data, including Erythrocyte Sedimentation Rate (ESR) and smoking status, were collected and analyzed.Results: A significant negative correlation was observed between infliximab trough levels and ADA levels (r = -0.69, p < 0.001). A notable 33.8% of patients developed high ADA titers (>100 ng/mL). ESR and smoking were significantly associated with lower infliximab levels and higher ADA levels. Other factors, such as hormones (Free T4, TSH), vitamins, and kidney and liver function tests, did not show significant correlations.Conclusion: This study provides the first evidence from Jordan supporting the utility of TDM for infliximab. The high prevalence of ADAs and their correlation with negative clinical outcomes underscore the need for routine TDM to guide dosing strategies and improve patient outcomes in Jordan. The findings also highlight ESR and smoking as potential risk factors for treatment failure.

Journal of Research in PharmacyVol. 30(6)
Petra University (JO)
University of Petra
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon